Checkmate Pharmaceuticals, Inc.
CMPIInactive ticker- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
No open-market purchases or sales by Checkmate Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Checkmate Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Checkmate Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Powell Michael | Director | – | May 31, 2022 | 0 |
| Fuhrman Alan | Director | – | May 31, 2022 | 0 |
| Flaherty Keith T. | Director | – | May 31, 2022 | 0 |
| Wigginton Jon Marc | Director | – | May 31, 2022 | 0 |
| Wooldridge James | Chief Medical Officer | – | May 31, 2022 | 0 |
| Isacoff Oren | Director | – | May 31, 2022 | 0 |
| Colabuono Peter | Director | – | May 31, 2022 | 0 |
| Dolski Robert | Chief Financial Officer | – | May 31, 2022 | 0 |
| Yan Joy | Director | – | May 31, 2022 | 0 |
| Bash Alan | Chief Executive Officer | – | May 31, 2022 | 0 |
| Goodman Corey S | 10% Owner | 2,155,930 | May 17, 2022 | 0 |
| Adelman Robert J | 10% Owner | 2,155,930 | May 17, 2022 | 0 |
| venBio Global Strategic Fund II L.P. | 10% Owner | 2,155,930 | May 17, 2022 | 0 |
| venBio Global Strategic GP II, Ltd. | 10% Owner | 2,155,930 | May 17, 2022 | 0 |
| venBio Global Strategic GP II, L.P. | 10% Owner | 2,155,930 | May 17, 2022 | 0 |
| Novo Holdings A/S | 10% Owner | 2,161,990 | Feb 25, 2022 | 0 |
| Labinger Barry | President and CEO | – | Aug 6, 2021 | 0 |
| Chaudhary Kleem | Chief Business Officer | – | Aug 6, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 17, 2022 (view filing)5:12 PM ET | May 13-16 | 4 days | Goodman Corey S and 4 others10% Owner | SSale | −131.7K | $10.45 | −$1.38M | −5.8%2.16M after | 2 lots |
| May 12, 2022 (view filing)8:47 PM ET | May 10-12 | 2 days | Goodman Corey S and 4 others10% Owner | SSale | −160.9K | $10.39 | −$1.67M | −6.6%2.29M after | 3 lots |
| May 9, 2022 (view filing)6:58 PM ET | May 5-9 | 4 days | Goodman Corey S and 4 others10% Owner | SSale | −86.7K | $10.37 | −$898.9K | −3.4%2.45M after | 3 lots |
| May 4, 2022 (view filing)7:30 PM ET | May 2-4 | 2 days | Goodman Corey S and 4 others10% Owner | SSale | −270.7K | $10.38 | −$2.81M | −9.6%2.54M after | 3 lots |
| Apr 29, 2022 (view filing)5:50 PM ET | Apr 27-29 | 2 days | Goodman Corey S and 4 others10% Owner | SSale | −190.0K | $10.38 | −$1.97M | −6.3%2.81M after | 3 lots |
| Apr 26, 2022 (view filing)6:40 PM ET | Apr 22-26 | 4 days | Goodman Corey S and 4 others10% Owner | SSale | −129.8K | $10.39 | −$1.35M | −4.2%3.00M after | 3 lots |
| Apr 21, 2022 (view filing)8:54 PM ET | Apr 19-21 | 2 days | Goodman Corey S and 4 others10% Owner | SSale | −547.7K | $10.41 | −$5.70M | −14.9%3.13M after | 3 lots |
| Feb 25, 2022 (view filing) | Feb 23-25 | 2 days | Novo Holdings A/S10% Owner | SSale | −8.11K | $2.84 | −$23.0K | −0.4%2.16M after | 3 lots |